Skip to main content

Immunotherapy in Alzheimer's disease

Edited by Philip Scheltens

This series of articles, published in Alzheimer's Research & Therapy, has not been sponsored. All articles have undergone the journal’s standard peer review process overseen by the Series Editor, with final decisions made by the Editors in Chief. The Series Editor and Editors in Chief declare no competing interests.

  1. The symptomatic drugs currently on the market for Alzheimer’s disease (AD) have no effect on disease progression, and this creates a large unmet medical need. The type of drug that has developed most rapidly i...

    Authors: Lars Lannfelt, Christer Möller, Hans Basun, Gunilla Osswald, Dag Sehlin, Andrew Satlin, Veronika Logovinsky and Pär Gellerfors
    Citation: Alzheimer's Research & Therapy 2014 6:16
  2. Alzheimer’s disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protei...

    Authors: Bengt Winblad, Ana Graf, Marie-Emmanuelle Riviere, Niels Andreasen and J Michael Ryan
    Citation: Alzheimer's Research & Therapy 2014 6:7
  3. Perhaps more definitively than any other class of novel Alzheimer’s disease (AD) therapy, pre-clinical studies in mouse models of amyloid β (Aβ) deposition have established the disease-modifying potential of a...

    Authors: Todd E Golde
    Citation: Alzheimer's Research & Therapy 2014 6:3